Dasatinib and nilotinib are associated with similar response rates and survival outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP).
For patients with chronic myeloid leukemia treated with lifelong targeted therapies, social support is crucial for maintaining psychological well-being.
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) plus ponatinib appears to be superior to hyper-CVAD plus dasatinib for the frontline treatment of patients with Philadelphia chromosome-positive ALL.
Patients with acute myeloid leukemia (AML) harboring mutations in the TP53 gene have worse complete remission rates and durations and overall survival regardless of age or the type of treatment received.
Tyrosine Kinase Inhibitor Therapy Can Be Safely Stopped in Select Patients With CML in Chronic PhaseJuly 29, 2016
A high percentage of patients with CML treated with TKIs achieve deep molecular responses and can safely stop therapy. Initials results of the EURO-SKI trial define prognostic markers that indicate durability of deep molecular responses after stopping TKI therapy.
Mogamulizumab induced an encouraging response rate in patients with relapsed/refractory adult T-cell leukemia/lymphoma.
Telomere length is predictive for determining which children treated for AML are at highest risk for delayed recovery, a finding that may have significant implications for treatment-related morbidity and mortality.
In the era of tyrosine kinase inhibitors and allogeneic hematopoietic cell transplantation, the life expectancy of patients with CML is approaching that of the general population.
A study examined the impact of post-transplant maintenance TKIs on patients with Ph+ acute lymphoblastic leukemia and chronic myeloid leukemia.
Recently Identified Biomarkers Found to Warn of Chronic Graft-vs-Host Disease in Marrow Transplant PatientsJuly 01, 2016
Researchers recently identified CXCL10, a protein that could act as a biomarker for chronic graft-versus-host disease (cGVHD), a long-term adverse effect that develops in some patients after undergoing blood and bone marrow transplant.
Ibrutinib treatment for chronic lymphocytic leukemia with the deletion of chromosome 17p (del17p CLL) increases the percentage of patients alive at 30 months over other therapies for del17p CLL.
In a randomized phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with ALL whose disease had relapsed following standard therapies, qualified for stem cell transplants after treatment with the drug.
Event-free survival for adult patients with ALL has improved from 40% to 73% with the implementation of the NOPHO ALL 2008 protocol in July 2008.
Deep and durable remissions were produced by the combination of SGN-CD33A and hypomethylating agents among patients with acute myeloid leukemia (AML).
Overall survival for patients with acute lymphoblastic leukemia (ALL) was nearly doubled to 7.8 months from 4.0 months by treating patients with blinatumomab compared with standard of care.
Pediatric patients with ALL treated with methotrexate can experience challenges with mental flexibility and organization compared with expectations from the general population.
New research indicates that rituximab maintenance therapy can extend progression-free survival in patients with chronic lymphocytic leukemia achieving at least a partial response to induction therapy with rituximab and chemotherapy.
Researchers revealed a pathway in cell culture and mice by which salicylic acid decreases inflammation and by which salicylic acid and diflunisal decrease cancerous growth.
Prognostic Index Will Improve Clinical Practice Management of Patients With CLL and in Clinical TrialsJune 10, 2016
An international consortium devised an international prognostic index for chronic lymphocytic leukemia (CLL-IPI) that combines genetic, biochemical, and clinical parameters into a prognostic model to enable more targeted management of patients with CLL.
The FLT3 tyrosine kinase is the most frequent mutation found in AML, and targeting CDK6 with palbociclib may be an effective strategy against AML.
The US FDA has granted Priority Review to ofatumumab used in combination with fludarabine and cyclophosphamide for the treatment of chronic lymphocytic leukemia.
Response to T-cell Immunotherapy Promising for Patients With Advanced B-cell Acute Lymphocytic LeukemiaMay 20, 2016
Remission was achieved for 27 of 29 patients with advanced B cell acute lymphocytic leukemia (ALL) in an early phase trial of CAR T cells.
Cancer stem cells that drive tumor growth were halved by MEDI-551, an experimental antibody treatment for multiple myeloma, according to results of a small preliminary clinical trial.
Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomasApril 21, 2016
[Blood and Lymphatic Cancer: Targets and Therapy] This research examines the clinical trial data using idelalisib as monotherapy or in combination with rituximab for the treatment of indolent B-cell malignancies.
Dozens of targeted therapies, which are preferred as treatment over chemotherapy and surgery, suppress the activity of T cells that could help to fight tumors.
Ponatinib treatment was compared with imatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CP-CML).
[Clinical Oncology in Adolescents and Young Adults] This research reviews the outcomes with chemotherapy alone and with hematopoietic stem cell transplantation in acute lymphoblastic leukemia, and examines the challenges faced in determining the best therapy for the adolescents and young adult patient population.
With the January 2016 expiration of the patent on Gleevac, significant cost savings can be realized by insurance companies and patients. Just 15 years ago, Gleevac (imatinib) changed chronic myeloid leukemia (CML) from a fatal disease to a treatable illness.
A short-chain fatty acid made by bacteria in the gut could play an important role in GVHD after allogeneic bone marrow transplant in mice. In human patients who receive bone marrow transplants, GVHD can cause severe gut damage.
New research has shed light on how the blood is produced in the body, and this work, done in mice, moves science a step closer to manipulation of blood stem cell creation. This could reduce the need for bone marrow transplants, such as those needed by patients with cancer.
- Helicobacter Pylori and Cancer Risk (Fact Sheet)
- Social Media Platforms Assist Cancer Patients During Treatment Journey in Many Ways
- Massage Therapy Promising for Pain, Anxiety in Patients With Cancer
- Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple Myeloma
- Weight Loss Through Diet Improves Risks for Cancer in Overweight/Obese Women
- Exercise is as Effective in Treating Metastatic Prostate Cancer as Medication
- Walnut Consumption Changes Gut Microbiome, Decreases Growth of Colon Cancer in Mice
- Triple-Drug Therapy Produces Response in Triple-Negative Breast Cancer, Mouse Study Shows
- Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma
- Study Supports Increased Role for Surgery in Multimodality Therapy for Early Stage SCLC
- Breast Cancer Tumors Often a Composite of Tumor Types, Enhancing Treatment Resistance
- Coexisting Diabetes Increases Hospitalizations and Lengths of Stay in Solid-Organ Malignancies
- SES Factors Impact Survival of Younger Patients With Myeloma
- Insurance Status Affects Anticoagulant Selection in Patients With Cancer
- Hormone Receptor Test Results in DCIS Core Needle Biopsy Not Used, Not Needed
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|